Linda Morrow

4.5k total citations · 1 hit paper
81 papers, 3.6k citations indexed

About

Linda Morrow is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Linda Morrow has authored 81 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Endocrinology, Diabetes and Metabolism, 36 papers in Surgery and 25 papers in Molecular Biology. Recurrent topics in Linda Morrow's work include Diabetes Management and Research (34 papers), Diabetes Treatment and Management (30 papers) and Pancreatic function and diabetes (29 papers). Linda Morrow is often cited by papers focused on Diabetes Management and Research (34 papers), Diabetes Treatment and Management (30 papers) and Pancreatic function and diabetes (29 papers). Linda Morrow collaborates with scholars based in United States, Sweden and Canada. Linda Morrow's co-authors include Marcus Hompesch, Mark Kipnes, Sunder Mudaliar, Paul Dillon, Д. А. Шапиро, Paul Clopton, Robert R. Henry, Hanns–Ulrich Marschall, Mark Pruzanski and Luciano Adorini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Linda Morrow

76 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

2013 767 citations Sunder Mudaliar, Robert R. Henry et al. Gastroenterology profile →

Peers

Countries citing papers authored by Linda Morrow

Since Specialization

Citations

This map shows the geographic impact of Linda Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Morrow more than expected).

Fields of papers citing papers by Linda Morrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Morrow. The network helps show where Linda Morrow may publish in the future.

Co-authorship network of co-authors of Linda Morrow

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Morrow. A scholar is included among the top collaborators of Linda Morrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Morrow. Linda Morrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disability and Accommodation Use in US Bachelor of Science in Nursing Programs 2025 ·JAMA Network Open ·Brandy Jackson, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Krista Jones, Linda Morrow, (unknown), (unknown), Anna Valdez, Lisa M. Meeks	0
2	Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis 2023 ·Alimentary Pharmacology & Therapeutics ·Naim Alkhouri, Donald J. Lazas, Rohit Loomba, Juan P. Frías, Shibao Feng, Leo Tseng, Kemal Balic, Germaine D. Agollah, (unknown), Janani Iyer, Linda Morrow, Hank Mansbach, Maya Margalit, Stephen A. Harrison	8
3	Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study 2022 ·The Lancet. Gastroenterology & hepatology ·Rohit Loomba, Eric Lawitz, Juan P. Frías, Grisell Ortiz‐Lasanta, L. E. B. Johansson, (unknown), Linda Morrow, Moti Rosenstock, Cynthia L. Hartsfield, Chaoyin Chen, Leo Tseng, (unknown), Hank Mansbach, Maya Margalit	72
4	Incorporating protein precipitation to resolve hybrid IP-LC-MS assay interference for ultrasensitive quantification of intact therapeutic insulin dimer in human plasma 2022 ·Journal of Pharmaceutical and Biomedical Analysis ·Li Sun, Yang Xu, (unknown), Melanie Anderson, Sheila Breidinger, Pavan Vaddady, Bob Thornton, Linda Morrow, Randolph P. Matthews, S. Aubrey Stoch, Eric Woolf	1
5	Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers 2021 ·Neuropsychopharmacology ·Frederico G. S. Toledo, William Martin, Linda Morrow, Carine Beysen, Daiva Bajorunas, Ying Jiang, Bernard L. Silverman, David McDonnell, Mark Namchuk, John W. Newcomer, Christine Graham	8
6	An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension 2019 ·Diabetologia ·John P. Hanrahan, Jelena Seferović, James Wakefield, Phebe Wilson, (unknown), Joon Jung, Kenneth E. Carlson, Daniel P. Zimmer, Andrew L. Frelinger, Alan D. Michelson, Linda Morrow, Michael Hall, Mark G. Currie, G. Todd Milne, Albert T. Profy	27
7	Implementing a Just Culture: Perceptions of Nurse Managers of Required Knowledge, Skills and Attitudes 2017 ·Nursing leadership ·(unknown), Linda Morrow, (unknown), (unknown)	7
8	Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus 2014 ·Clinical Therapeutics ·Marcus Hompesch, Linda Morrow, (unknown), Carsten Roepstorff, Henrik F. Thomsen, Hanne Haahr	14
9	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial 2014 ·Metabolism ·Peter Stein, Jolene Kay Berg, Linda Morrow, David Polidori, (unknown), Sarah Rusch, Nicole Vaccaro, Damayanthi Devineni	43
10	Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease breakdown → 2013 ·Gastroenterology ·Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal, Linda Morrow, Hanns–Ulrich Marschall, Mark Kipnes, Luciano Adorini, (unknown), Paul Clopton, Erin Castelloe, Paul Dillon, Mark Pruzanski, Д. А. Шапиро	767
11	Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin 2012 ·Diabetes Obesity and Metabolism ·Damayanthi Devineni, Linda Morrow, Marcus Hompesch, Donna Skee, An Vandebosch, Joseph Murphy, Kirk Ways, Sherwyn Schwartz	192
12	Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers 2011 ·Diabetes Technology & Therapeutics ·Linda Morrow, Douglas B. Muchmore, Elizabeth Ludington, Daniel E. Vaughn, Marcus Hompesch	14
13	Continuous Glucose Monitoring Using a Novel Glucose/Galactose Binding Protein: Results of a 12-Hour Feasibility Study with the Becton Dickinson Glucose/Galactose Binding Protein Sensor 2011 ·Diabetes Technology & Therapeutics ·(unknown), Linda Morrow, (unknown), (unknown), (unknown), (unknown), Bruce C. Roberts, (unknown), Kristin Weidemaier, Khin Maung Win, Marcus Hompesch	17
14	Short‐term metabolic effects of prednisone administration in healthy subjects 2011 ·Diabetes Obesity and Metabolism ·Eunkyung Kauh, Lori Mixson, Sudha S. Shankar, (unknown), (unknown), Linda Morrow, Lutz Heinemann, M. Ruddy, Gary Herman, David E. Kelley, Marcus Hompesch	17
15	Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes 2010 ·European Journal of Endocrinology ·Scott M. Ocheltree, Marcus Hompesch, (unknown), Linda Morrow, (unknown), Scott J. Jacober	20
16	Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction 2010 ·Diabetes Obesity and Metabolism ·Linda Morrow, Marcus Hompesch, H. D. Guthrie, Douglas C. Chang, (unknown)	34
17	A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY 2009 ·Hepatology ·(unknown), Sunder Mudaliar, (unknown), (unknown), Linda Morrow, (unknown), Paul Dillon, Paul Clopton, Mark Kipnes, Д. А. Шапиро	18
18	Aging and Insulin Sensitivity: Role of Blood Pressure and Sympathetic Nervous System Activity 1993 ·Journal of Gerontology ·Mark A. Supiano, Robert Hogikyan, Linda Morrow, (unknown), William H. Herman, Andrzej T. Gałecki, Jeffrey B. Halter	23
19	Risk Assessment for Pressure Ulcers: An Adaptation of the National Pressure Ulcer Advisory Panel Risk Factors to Spinal Cord Injured Patients 1993 ·PubMed ·Paula A. Rochon, Marie P. Beaudet, (unknown), Linda Morrow, (unknown), Robert R. Young, Kenneth L. Minaker	31
20	Norepinephrine metabolism in humans. Kinetic analysis and model. 1987 ·Journal of Clinical Investigation ·Óscar Linares, John A. Jacquez, Loren A. Zech, (unknown), (unknown), Linda Morrow, S. G. Rosen, Jeffrey B. Halter	60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact